Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary (MESA-COPD)
The Multi-Ethnic Study of Atherosclerosis (MESA) - Chronic Obstructive Pulmonary Disease (COPD) Study aims to characterize the pulmonary vascular changes and their biology in early COPD using imaging, gene expression profiling and peripheral cellular measures.
Chronic Obstructive Pulmonary Disease
|Study Design:||Time Perspective: Prospective|
|Official Title:||Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary (MESA-COPD)|
- Changes in cardiac structure and pulmonary vascular structure and function [ Time Frame: Up to 2 years from start of study ] [ Designated as safety issue: No ]
Cardiac structure: changes in right ventricular (RV) mass, RV mass/Right Ventricular End-Diastolic Volume (RV-EDV)
Pulmonary structure: changes in total pulmonary vascular volume (TPVV) and pulmonary artery (PA) perfusion
Function: changes in PA flow and distensibility
- Numbers of CD31+/CD42 endothelial microparticles (EMPs) [ Time Frame: Up to 2 years from the start of study ] [ Designated as safety issue: No ]Numbers of CD31+/CD42 EMPs reflective of apoptosis are elevated; They are abnormal in severe, moderate and mild COPD compared to controls.
- Numbers of circulating endothelial cells (CEC) [ Time Frame: Up to 2 years from the start of study ] [ Designated as safety issue: No ]Numbers of circulating endothelial cells (CEC), resulting from endothelial injury, are elevated. They are abnormal in severe, moderate and mild COPD compared to controls
- Numbers of endothelial progenitor cells (EPCs), involved in endothelial repair, are decreased [ Time Frame: Up to 2 years from the start of study ] [ Designated as safety issue: No ]They are abnormal in severe, moderate and mild COPD compared to controls.
Biospecimen Retention: Samples With DNA
Blood will be stored at Columbia and at University of Vermont, identified only by study ID and following standard procedures. It will be accessible only to study investigators and, if the participant approves, outside investigators following MESA/NIH protocols and with IRB approval. Blood will be kept indefinitely.
|Study Start Date:||May 2009|
|Estimated Study Completion Date:||July 2016|
|Estimated Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in the US and will soon replace stroke as the third leading cause.
Translation of promising biological hypotheses of COPD pathogenesis to human populations that may lead to new therapies is urgently needed. The vascular hypothesis of COPD was articulated almost 50 years ago. Bench research on endothelial dysfunction in COPD is evolving rapidly and has shown that acrolein in cigarette smoke causes endothelial apoptosis and endothelial apoptosis is directly implicated in COPD pathogenesis. Clinical studies on endothelial dysfunction and vascular changes in COPD are limited.
The proposed study is a longitudinal study of smokers nested among the MESA-Lung (AAAA7791) and EMphysema and Cancer Action Project (EMCAP) Studies (AAAA6484), which together provide a well-defined cohort of 4,617 participants with prior spirometry and CT measures.
The Multiethnic Study of Atherosclerosis - Chronic Obstructive Pulmonary Disease (MESA COPD Study) has two main scientific purposes:
- characterize the pulmonary vascular changes in COPD and their biology, and
- propose novel pathways for new therapies in COPD.
MESA COPD is a longitudinal study of smokers nested within the MESA-Lung and EMCAP cohorts of 360 participants (160 cases with mild, 60 cases with moderate and 40 cases with severe COPD and 100 controls) who will be phenotyped with magnetic resonance (MR) pulmonary angiography, pulmonary function testing, full-lung CT scans, serum Vascular Endothelial Growth Factor (VEGF), cell assays and gene expression profiling. MESA COPD Study will contribute improving the knowledge of early changes in COPD that may lead to novel disease-modifying medical therapies and preventative strategies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01397721
|United States, New York|
|New York, New York, United States, 10032|
|Principal Investigator:||R. Graham Barr, M.D., Dr.PH.||Columbia University|